SlideShare a Scribd company logo
1 of 55
Detection of small intragenic deletions using targeted comparative genomic hybridization
Today’s agenda ,[object Object],[object Object],[object Object]
Innovative clinical genetics and diagnostic  solutions to advance molecular medicine  ,[object Object],[object Object],[object Object],[object Object],OGT Begbroke:  Corporate offices and high throughput labs OGT Southern Centre:  Biomarker discovery
CytoSure cytogenetics range    high quality data    meaningful results    standardisation ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],* Not available in USA
The OGT aCGH design process aCGH arrays All possible human genome probes Oligome TM  database Further selection based on OGT probe rating and desired coverage and content Selection based on specificity, T m , GC, etc. Design & hyb two different aCGH arrays Optimised aCGH design =  PRODUCT Selection of best performing probes based on experimental results
Today’s agenda ,[object Object],[object Object],[object Object]
Detection of Small intragenic Deletions Using Targeted Comparative Genomic Hybridization MadhuriHegde, Ph.D., FACMG Associate Professor Scientific Director, Emory Genetics Laboratory Department of Human Genetics Emory University Atlanta, GA
Scherer et al. (2007) Nat Genet 39:s7-s15 Genomic Variation G-banded karyotype FISH Microarray (~5 Mb)
aCGH FISH MLPA  Real-Time PCR Deletion/Duplication Detection Methodology  in clinical diagnostics
Purpose With the help of few examples of small deletions mapped in our laboratory,  -illustrate the success of this technology -demonstrate the detection limits, and -discuss the lessons learnt thus far  Scope Small intragenic deletions (~2.5 kb and shorter)
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],obvious ones Near the detection limit
Probe distribution A.  GeneTargeted C.  Whole Genome B.  GeneTargeted with Backbone
Probe density Keeping a balance: decrease redundancy while not compromising of sensitivity Duplication of Ex44
Exon-centric multi-gene high density array Designed to detect CNVs encompassing single and multiple exon Increase the cost-effectiveness without compromising on sensitivity
4x180k 4x180k 8x60k   EGL_XLIDplus_v2 EGL_NMD_NBSplus_v2 EGL_DMDplus_V2           ASD 8784 ASD 8784     Cancer 9598 Cancer 9598     CDG 4908 CDG 4908     Congenital abnormality 13373 Congenital abnormality 13373     Congenital heart disease 16421 Congenital heart disease 16421     Cystic 12271 Cystic 12271         Diabetes 941     Eyes 961 Eyes 961     Growth disorder 51 Growth disorder 51         Hearing Loss 2392     Hemoglobinopathy 42 Hemoglobinopathy 42         Leukodystrophy 2273         LSD 6596         Metabolic 8742     Mitochondrial 485 Mitochondrial 485     MR 7704             NBS 14149         NMD 47414 NMD 47414 Others 5874 Others 5874     XLMR 77999                 DMD 12713
Examples of intragenic deletions
Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Autosomal dominant inheritance 37 year old male personal and a family history of multiple cutaneousleiomyomatosis
exons 10  9  8  7  6  5  4  3  2  1 Familial mutation: Deletion  ~  19 kb  encompassing exon 2 to 9 of the  FH  gene FH  gene (~22 kb) +1 -1 0 Deletion  ~ 19 kb
2 year old East Indian male with a biochemical diagnosis of MSUD.  Maple Syrup Urine Disease Autosomal Recessive inheritance c.871C>T (p.R291X) nonsense mutation in exon 7 of  DBT  gene identified
-0.6 ~-0.8 exons 11  5  4  3  2  1 Deletion  ~  3.7 kb  encompassing exon 5of the  DBT  gene DBT  gene (~63 kb) +1 -1 0 Deletion  3.7 kb
Even Shorter Intragenic Deletions (< 2.5 kb)
PAH Phenylketonuria (PKU) Autosomal recessive inheritance - two mutations in trans  Metabolic disorder - biochemical profile adds to clinical suspicion
Patient Reference G AA  Glutamicacid A AA  Lysine  Patient Reference Exon 12  Intron 12 PKU case 1 ,[object Object],[object Object],[object Object],Established patient of PKU Currently enrolled in the Kuvan study at Emory One copy of the c.838G>A (p.E280K) missense mutation in exon 7 of  PAH  gene PKU case 2 ,[object Object],[object Object],[object Object],Picked up on NBS, Elevated plasma phenylalanine.  One copy of the IVS12+1G>A splice donor site mutation
exons PAH  gene (~79 kb) 13  9  6  3  1 PKU case 1 PKU case 2
868 bp 1,286 bp Exon 6 Exon 7 Two unrelated individuals with the same deletion PKU case 1 PKU case 2 PAH  gene
Allele 1  1134 bp Allele 2  ~350 bp 100 200 300 case 1  case 2 Allele specific PCR
Green: Repeat masker Red: polymorphisms (SNP) CAPITAL: exon Underlined: primers Breakpoint within a SINE: MIRb family Breakpoint within a exon 6 Red box: “CT” is the microhomology at breakpoints.
868 bp 1,286 bp 800 bp 800 bp Partial exon 6 deletion Exon 6 Exon 7 Intron 6 PKU case 1 PKU case 2 Note: breakpoint within an element
STK11 Peutz-Jeghers syndrome (PJS) Autosomal dominant inheritance - one mutation Clinical Presentation & Family History
[object Object],[object Object],[object Object],Personal history of polyps and intussusceptions and  family history of cancer; paternal aunt with breast cancer and paternal grandmother with pancreatic cancer.
exons STK11  gene (~22 kb) +1 -1 0 1  2  3  4,5 6  7  8  9  10
+1 -1 0 Possible deletion encompassing exon 3 Designing allele specific PCR 1076 bp exons 2  3  4 AluY Exon3 Intron2 Intron3 Exon2 Exon 4 Intron1 INT1_1F ex2_1F INT2_1F INT2_2F INT2_3F INT3_1R INT3_2R INT3_3R INT3_4R and INT3_5R
Exon3 Intron2 Intron3 Exon2 Exon 4 Intron1 INT2_2F INT3_1R INT3_2R INT3_3R INT3_4R and INT3_5R Data indicates a possible deletion of ~1kb.  Expected band size in bp Possible exon 3 deletion  678 1130 1324 1580 1595
Proximal breakpoint 1170072 in intron 2 Distal breakpoint 1171039 in intron 3 Reference Reference Patient Patient
+1 -1 0 Note: breakpoints outside of element A few probes that did not perform ideally were unique exons 2  3  4 1076 bp 967 bp AluY
HPRT1 Lesch-Nyhan Syndrome X-linked inheritance - one mutation Clinical Presentation & Family History
Lesch-Nyhan case Pending prenatal 24 year old female for carrier testing for a familial  HPRT1  mutation ? ?
exons HPRT1  gene (~40.5 kb) 1  2  3  4  5  6  7,8  9 +1 -1 0 -5 ? ?
2,780 bp Exon 5 is 18 bp +1 -1 0 -5
Exon 5 Max (2757bp) Min (381bp) Int4_1 Int4_2 Int4_3 Int4_4 Intron 4 Intron 5 Int5_4 HPRT_Int5_5R Int5_6 Int5_2 Int5_1 Int5_3 Int5_5 HPRT_Int4_1F HPRT_Int4_2F HPRT_Int5_5R 2745 bp fragment expected  in wild type 2657 bp fragment expected in wild type 88bp size difference 500- 400- 300- 500- 400- 300-
Mapped a total of 380 bp in the amplicon 157 bp of intron 4 69 bp insertion 154 bp of intron 5 157 bp of intron 4 69 bp insertion
The Inserted 69 bpsequence match best on a gene desert on Chromsome 5. ATTCTAGTGATGTTTTCAGGCCTCAGGGGGCGGGTTGGGGGTGGTGGAGGTGGTGTGTATAATATCACT
EMD case ,[object Object],[object Object],[object Object]
Wt Ex1  Ex2  Ex3  Ex1  Ex2  Ex3  Ex1  Ex2  Ex3  Pt. water Exon 1 and 2 did not amplify for the patient
exons EMD  gene (~2 kb) +1 -1 0 1  2  3  4  5  6 -2 -3 -4 -5
exons 1  2 252 bp +1 -1 0 -5
Wt expected band  with 1F/2R Would be 480 bp For Wt expected band  with 1F/3R Would be 677 bp Band ~370 bp Suggesting ~300 bp deletion Band ~170 bp Suggesting ~300 bp deletion Forward Primer  1F  1F Reverse Primer  2R  3R Wt  Pt.  H2O  Wt  Pt.  H2O  1kb+ -100 -200 -300 -400 -500 -650 -850 -------1000
exon1 exon2 Red nucleotides are deleted. Exons are capitalized Microhomology is limited to two nucleotides, “GC”
Deletion encompassing Partial exon 1 and entire exon 2 exons 1  2 252 bp 366 bp +1 -1 0 -5
Conclusions ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Acknowledgements Directors: Bradford Coffee Ph.D. FACMG Lora Bean Ph.D. FACMG Katie Rudd Ph.D. FACMG Alice Tanner Ph.D. C.G.C. SyedHussainAskree, MBBS, PhD EphremLip Hon Chin, BS (Tech), CLSp (MB)
Today’s agenda ,[object Object],[object Object],[object Object]
Modified Emory panel designs — available now! ,[object Object],[object Object],Visit booth 416 for disorder lists and special introductory offer
Disorders covered ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],* Not available in US.
Thank you www.ogt.co.uk

More Related Content

What's hot

Platelet Endo Meeting Feb2009
Platelet Endo Meeting Feb2009Platelet Endo Meeting Feb2009
Platelet Endo Meeting Feb2009guest7d5b8c
 
The Yoyo Has Stopped: Reviewing the Evidence for a Low Basal Human Protein...
The Yoyo Has Stopped:  Reviewing the Evidence for a Low Basal Human Protein...The Yoyo Has Stopped:  Reviewing the Evidence for a Low Basal Human Protein...
The Yoyo Has Stopped: Reviewing the Evidence for a Low Basal Human Protein...Chris Southan
 
Why Y Chromosome Markers are an Ever Expanding Essential Tool in Sexual Assau...
Why Y Chromosome Markers are an Ever Expanding Essential Tool in Sexual Assau...Why Y Chromosome Markers are an Ever Expanding Essential Tool in Sexual Assau...
Why Y Chromosome Markers are an Ever Expanding Essential Tool in Sexual Assau...Thermo Fisher Scientific
 
Translating Genomes | Personalizing Medicine
Translating Genomes | Personalizing MedicineTranslating Genomes | Personalizing Medicine
Translating Genomes | Personalizing MedicineCandy Smellie
 
Whole Exome Sequencing at Stanford University
Whole Exome Sequencing at Stanford UniversityWhole Exome Sequencing at Stanford University
Whole Exome Sequencing at Stanford UniversityGolden Helix
 
Genes in complex neurological disorders
Genes in complex neurological disordersGenes in complex neurological disorders
Genes in complex neurological disordersDenise Sheer
 
Dr. John Svaren - 'Neuropatías periféricas hereditarias'
Dr. John Svaren - 'Neuropatías periféricas hereditarias'Dr. John Svaren - 'Neuropatías periféricas hereditarias'
Dr. John Svaren - 'Neuropatías periféricas hereditarias'Fundación Ramón Areces
 
Gene editing 1
Gene editing 1Gene editing 1
Gene editing 1ajayveeru
 
Triple Screen FINAL poster-3
Triple Screen FINAL poster-3Triple Screen FINAL poster-3
Triple Screen FINAL poster-3Whitney Best
 
Treatment for lysosomal storage diseases using crispr cas9
Treatment for lysosomal storage diseases using crispr cas9Treatment for lysosomal storage diseases using crispr cas9
Treatment for lysosomal storage diseases using crispr cas9limchloe
 
Bioinformatic data analysis – comparison from three human studies using diffe...
Bioinformatic data analysis – comparison from three human studies using diffe...Bioinformatic data analysis – comparison from three human studies using diffe...
Bioinformatic data analysis – comparison from three human studies using diffe...Agnieszka Caruso
 
Eradicating diseases (genome)
Eradicating diseases (genome)Eradicating diseases (genome)
Eradicating diseases (genome)Utkarsh Verma
 
GENASSIST™ CRISPR & rAAV Genome Editing Tools
GENASSIST™ CRISPR & rAAV Genome Editing ToolsGENASSIST™ CRISPR & rAAV Genome Editing Tools
GENASSIST™ CRISPR & rAAV Genome Editing ToolsCandy Smellie
 
Van criekinge next_generation_epigenetic_profling_vuppsala
Van criekinge next_generation_epigenetic_profling_vuppsalaVan criekinge next_generation_epigenetic_profling_vuppsala
Van criekinge next_generation_epigenetic_profling_vuppsalaProf. Wim Van Criekinge
 
Gene editing application for cancer therapeutics
Gene editing application for cancer therapeuticsGene editing application for cancer therapeutics
Gene editing application for cancer therapeuticsNur Farrah Dini
 

What's hot (20)

Platelet Endo Meeting Feb2009
Platelet Endo Meeting Feb2009Platelet Endo Meeting Feb2009
Platelet Endo Meeting Feb2009
 
The Yoyo Has Stopped: Reviewing the Evidence for a Low Basal Human Protein...
The Yoyo Has Stopped:  Reviewing the Evidence for a Low Basal Human Protein...The Yoyo Has Stopped:  Reviewing the Evidence for a Low Basal Human Protein...
The Yoyo Has Stopped: Reviewing the Evidence for a Low Basal Human Protein...
 
Why Y Chromosome Markers are an Ever Expanding Essential Tool in Sexual Assau...
Why Y Chromosome Markers are an Ever Expanding Essential Tool in Sexual Assau...Why Y Chromosome Markers are an Ever Expanding Essential Tool in Sexual Assau...
Why Y Chromosome Markers are an Ever Expanding Essential Tool in Sexual Assau...
 
Translating Genomes | Personalizing Medicine
Translating Genomes | Personalizing MedicineTranslating Genomes | Personalizing Medicine
Translating Genomes | Personalizing Medicine
 
Whole Exome Sequencing at Stanford University
Whole Exome Sequencing at Stanford UniversityWhole Exome Sequencing at Stanford University
Whole Exome Sequencing at Stanford University
 
Genes in complex neurological disorders
Genes in complex neurological disordersGenes in complex neurological disorders
Genes in complex neurological disorders
 
Dr. John Svaren - 'Neuropatías periféricas hereditarias'
Dr. John Svaren - 'Neuropatías periféricas hereditarias'Dr. John Svaren - 'Neuropatías periféricas hereditarias'
Dr. John Svaren - 'Neuropatías periféricas hereditarias'
 
Gene therapy
Gene therapyGene therapy
Gene therapy
 
Gene editing 1
Gene editing 1Gene editing 1
Gene editing 1
 
Triple Screen FINAL poster-3
Triple Screen FINAL poster-3Triple Screen FINAL poster-3
Triple Screen FINAL poster-3
 
155 dna microarray
155 dna microarray155 dna microarray
155 dna microarray
 
Bellander, Bo Michael
Bellander, Bo MichaelBellander, Bo Michael
Bellander, Bo Michael
 
Treatment for lysosomal storage diseases using crispr cas9
Treatment for lysosomal storage diseases using crispr cas9Treatment for lysosomal storage diseases using crispr cas9
Treatment for lysosomal storage diseases using crispr cas9
 
Embed Repro Test
Embed Repro TestEmbed Repro Test
Embed Repro Test
 
Bioinformatic data analysis – comparison from three human studies using diffe...
Bioinformatic data analysis – comparison from three human studies using diffe...Bioinformatic data analysis – comparison from three human studies using diffe...
Bioinformatic data analysis – comparison from three human studies using diffe...
 
Eradicating diseases (genome)
Eradicating diseases (genome)Eradicating diseases (genome)
Eradicating diseases (genome)
 
GENASSIST™ CRISPR & rAAV Genome Editing Tools
GENASSIST™ CRISPR & rAAV Genome Editing ToolsGENASSIST™ CRISPR & rAAV Genome Editing Tools
GENASSIST™ CRISPR & rAAV Genome Editing Tools
 
Van criekinge next_generation_epigenetic_profling_vuppsala
Van criekinge next_generation_epigenetic_profling_vuppsalaVan criekinge next_generation_epigenetic_profling_vuppsala
Van criekinge next_generation_epigenetic_profling_vuppsala
 
Cell death 2013
Cell death 2013Cell death 2013
Cell death 2013
 
Gene editing application for cancer therapeutics
Gene editing application for cancer therapeuticsGene editing application for cancer therapeutics
Gene editing application for cancer therapeutics
 

Similar to ACMG Workshop 2011

Characterizing Alzheimer’s Disease candidate genes and transcripts with targe...
Characterizing Alzheimer’s Disease candidate genes and transcripts with targe...Characterizing Alzheimer’s Disease candidate genes and transcripts with targe...
Characterizing Alzheimer’s Disease candidate genes and transcripts with targe...Integrated DNA Technologies
 
20081216 06陳倩琪 紅麴菌基因體之定序與分析
20081216 06陳倩琪 紅麴菌基因體之定序與分析20081216 06陳倩琪 紅麴菌基因體之定序與分析
20081216 06陳倩琪 紅麴菌基因體之定序與分析Monascus2008
 
Nextgenerationsequencing ngs 131218163555-phpapp02
Nextgenerationsequencing     ngs  131218163555-phpapp02Nextgenerationsequencing     ngs  131218163555-phpapp02
Nextgenerationsequencing ngs 131218163555-phpapp02鋒博 蔡
 
Nextgenerationsequencing 131218163555-phpapp02
Nextgenerationsequencing 131218163555-phpapp02Nextgenerationsequencing 131218163555-phpapp02
Nextgenerationsequencing 131218163555-phpapp02t7260678
 
Aug2013 Heidi Rehm integrating large scale sequencing into clinical practice
Aug2013 Heidi Rehm integrating large scale sequencing into clinical practiceAug2013 Heidi Rehm integrating large scale sequencing into clinical practice
Aug2013 Heidi Rehm integrating large scale sequencing into clinical practiceGenomeInABottle
 
Lessons learned from high throughput CRISPR targeting in human cell lines
Lessons learned from high throughput CRISPR targeting in human cell linesLessons learned from high throughput CRISPR targeting in human cell lines
Lessons learned from high throughput CRISPR targeting in human cell linesChris Thorne
 
2011 Rna Course Part 1
2011 Rna Course Part 12011 Rna Course Part 1
2011 Rna Course Part 1ICGEB
 
Molecular techniques for pathology research - MDX .pdf
Molecular techniques for pathology research - MDX .pdfMolecular techniques for pathology research - MDX .pdf
Molecular techniques for pathology research - MDX .pdfsabyabby
 
Clinical molecular diagnostics for drug guidance
Clinical molecular diagnostics for drug guidanceClinical molecular diagnostics for drug guidance
Clinical molecular diagnostics for drug guidanceNikesh Shah
 
Developing a Rapid Clinical Sequencing System to Classify Meningioma: Meet th...
Developing a Rapid Clinical Sequencing System to Classify Meningioma: Meet th...Developing a Rapid Clinical Sequencing System to Classify Meningioma: Meet th...
Developing a Rapid Clinical Sequencing System to Classify Meningioma: Meet th...QIAGEN
 
Making genome edits in mammalian cells
Making genome edits in mammalian cellsMaking genome edits in mammalian cells
Making genome edits in mammalian cellsChris Thorne
 
Arjun's Poster ACTUAL FINAL POSTER
Arjun's Poster ACTUAL FINAL POSTERArjun's Poster ACTUAL FINAL POSTER
Arjun's Poster ACTUAL FINAL POSTERArjun Mahadevan
 
In Vitro Characterization of a Novel Cis-acting Element (NCE) in the Cd4 Locus
In Vitro Characterization of a Novel Cis-acting Element (NCE) in the Cd4 Locus In Vitro Characterization of a Novel Cis-acting Element (NCE) in the Cd4 Locus
In Vitro Characterization of a Novel Cis-acting Element (NCE) in the Cd4 Locus Yordan Penev
 
Avacta Life Sciences Affimers Presentation Global Protein Engineering Summit ...
Avacta Life Sciences Affimers Presentation Global Protein Engineering Summit ...Avacta Life Sciences Affimers Presentation Global Protein Engineering Summit ...
Avacta Life Sciences Affimers Presentation Global Protein Engineering Summit ...AvactaLifeSciences
 
Genomics Technologies
Genomics TechnologiesGenomics Technologies
Genomics TechnologiesSean Davis
 
2007. stephen chanock. technologic issues in gwas and follow up studies
2007. stephen chanock. technologic issues in gwas and follow up studies2007. stephen chanock. technologic issues in gwas and follow up studies
2007. stephen chanock. technologic issues in gwas and follow up studiesFOODCROPS
 

Similar to ACMG Workshop 2011 (20)

Characterizing Alzheimer’s Disease candidate genes and transcripts with targe...
Characterizing Alzheimer’s Disease candidate genes and transcripts with targe...Characterizing Alzheimer’s Disease candidate genes and transcripts with targe...
Characterizing Alzheimer’s Disease candidate genes and transcripts with targe...
 
20081216 06陳倩琪 紅麴菌基因體之定序與分析
20081216 06陳倩琪 紅麴菌基因體之定序與分析20081216 06陳倩琪 紅麴菌基因體之定序與分析
20081216 06陳倩琪 紅麴菌基因體之定序與分析
 
Nextgenerationsequencing ngs 131218163555-phpapp02
Nextgenerationsequencing     ngs  131218163555-phpapp02Nextgenerationsequencing     ngs  131218163555-phpapp02
Nextgenerationsequencing ngs 131218163555-phpapp02
 
Nextgenerationsequencing 131218163555-phpapp02
Nextgenerationsequencing 131218163555-phpapp02Nextgenerationsequencing 131218163555-phpapp02
Nextgenerationsequencing 131218163555-phpapp02
 
Aug2013 Heidi Rehm integrating large scale sequencing into clinical practice
Aug2013 Heidi Rehm integrating large scale sequencing into clinical practiceAug2013 Heidi Rehm integrating large scale sequencing into clinical practice
Aug2013 Heidi Rehm integrating large scale sequencing into clinical practice
 
Lessons learned from high throughput CRISPR targeting in human cell lines
Lessons learned from high throughput CRISPR targeting in human cell linesLessons learned from high throughput CRISPR targeting in human cell lines
Lessons learned from high throughput CRISPR targeting in human cell lines
 
2011 Rna Course Part 1
2011 Rna Course Part 12011 Rna Course Part 1
2011 Rna Course Part 1
 
Molecular techniques for pathology research - MDX .pdf
Molecular techniques for pathology research - MDX .pdfMolecular techniques for pathology research - MDX .pdf
Molecular techniques for pathology research - MDX .pdf
 
Clinical molecular diagnostics for drug guidance
Clinical molecular diagnostics for drug guidanceClinical molecular diagnostics for drug guidance
Clinical molecular diagnostics for drug guidance
 
Developing a Rapid Clinical Sequencing System to Classify Meningioma: Meet th...
Developing a Rapid Clinical Sequencing System to Classify Meningioma: Meet th...Developing a Rapid Clinical Sequencing System to Classify Meningioma: Meet th...
Developing a Rapid Clinical Sequencing System to Classify Meningioma: Meet th...
 
Making genome edits in mammalian cells
Making genome edits in mammalian cellsMaking genome edits in mammalian cells
Making genome edits in mammalian cells
 
Alexia Chrysostomou (083707160)
Alexia Chrysostomou (083707160)Alexia Chrysostomou (083707160)
Alexia Chrysostomou (083707160)
 
Arjun's Poster ACTUAL FINAL POSTER
Arjun's Poster ACTUAL FINAL POSTERArjun's Poster ACTUAL FINAL POSTER
Arjun's Poster ACTUAL FINAL POSTER
 
In Vitro Characterization of a Novel Cis-acting Element (NCE) in the Cd4 Locus
In Vitro Characterization of a Novel Cis-acting Element (NCE) in the Cd4 Locus In Vitro Characterization of a Novel Cis-acting Element (NCE) in the Cd4 Locus
In Vitro Characterization of a Novel Cis-acting Element (NCE) in the Cd4 Locus
 
Dna microarray mehran- u of toronto
Dna microarray  mehran- u of torontoDna microarray  mehran- u of toronto
Dna microarray mehran- u of toronto
 
Faseb poster2007b
Faseb poster2007bFaseb poster2007b
Faseb poster2007b
 
20140710 6 c_mason_ercc2.0_workshop
20140710 6 c_mason_ercc2.0_workshop20140710 6 c_mason_ercc2.0_workshop
20140710 6 c_mason_ercc2.0_workshop
 
Avacta Life Sciences Affimers Presentation Global Protein Engineering Summit ...
Avacta Life Sciences Affimers Presentation Global Protein Engineering Summit ...Avacta Life Sciences Affimers Presentation Global Protein Engineering Summit ...
Avacta Life Sciences Affimers Presentation Global Protein Engineering Summit ...
 
Genomics Technologies
Genomics TechnologiesGenomics Technologies
Genomics Technologies
 
2007. stephen chanock. technologic issues in gwas and follow up studies
2007. stephen chanock. technologic issues in gwas and follow up studies2007. stephen chanock. technologic issues in gwas and follow up studies
2007. stephen chanock. technologic issues in gwas and follow up studies
 

ACMG Workshop 2011

  • 1. Detection of small intragenic deletions using targeted comparative genomic hybridization
  • 2.
  • 3.
  • 4.
  • 5. The OGT aCGH design process aCGH arrays All possible human genome probes Oligome TM database Further selection based on OGT probe rating and desired coverage and content Selection based on specificity, T m , GC, etc. Design & hyb two different aCGH arrays Optimised aCGH design = PRODUCT Selection of best performing probes based on experimental results
  • 6.
  • 7. Detection of Small intragenic Deletions Using Targeted Comparative Genomic Hybridization MadhuriHegde, Ph.D., FACMG Associate Professor Scientific Director, Emory Genetics Laboratory Department of Human Genetics Emory University Atlanta, GA
  • 8. Scherer et al. (2007) Nat Genet 39:s7-s15 Genomic Variation G-banded karyotype FISH Microarray (~5 Mb)
  • 9. aCGH FISH MLPA Real-Time PCR Deletion/Duplication Detection Methodology in clinical diagnostics
  • 10. Purpose With the help of few examples of small deletions mapped in our laboratory, -illustrate the success of this technology -demonstrate the detection limits, and -discuss the lessons learnt thus far Scope Small intragenic deletions (~2.5 kb and shorter)
  • 11.
  • 12. Probe distribution A. GeneTargeted C. Whole Genome B. GeneTargeted with Backbone
  • 13. Probe density Keeping a balance: decrease redundancy while not compromising of sensitivity Duplication of Ex44
  • 14. Exon-centric multi-gene high density array Designed to detect CNVs encompassing single and multiple exon Increase the cost-effectiveness without compromising on sensitivity
  • 15. 4x180k 4x180k 8x60k   EGL_XLIDplus_v2 EGL_NMD_NBSplus_v2 EGL_DMDplus_V2           ASD 8784 ASD 8784     Cancer 9598 Cancer 9598     CDG 4908 CDG 4908     Congenital abnormality 13373 Congenital abnormality 13373     Congenital heart disease 16421 Congenital heart disease 16421     Cystic 12271 Cystic 12271         Diabetes 941     Eyes 961 Eyes 961     Growth disorder 51 Growth disorder 51         Hearing Loss 2392     Hemoglobinopathy 42 Hemoglobinopathy 42         Leukodystrophy 2273         LSD 6596         Metabolic 8742     Mitochondrial 485 Mitochondrial 485     MR 7704             NBS 14149         NMD 47414 NMD 47414 Others 5874 Others 5874     XLMR 77999                 DMD 12713
  • 17. Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Autosomal dominant inheritance 37 year old male personal and a family history of multiple cutaneousleiomyomatosis
  • 18. exons 10 9 8 7 6 5 4 3 2 1 Familial mutation: Deletion ~ 19 kb encompassing exon 2 to 9 of the FH gene FH gene (~22 kb) +1 -1 0 Deletion ~ 19 kb
  • 19. 2 year old East Indian male with a biochemical diagnosis of MSUD. Maple Syrup Urine Disease Autosomal Recessive inheritance c.871C>T (p.R291X) nonsense mutation in exon 7 of DBT gene identified
  • 20. -0.6 ~-0.8 exons 11 5 4 3 2 1 Deletion ~ 3.7 kb encompassing exon 5of the DBT gene DBT gene (~63 kb) +1 -1 0 Deletion 3.7 kb
  • 21. Even Shorter Intragenic Deletions (< 2.5 kb)
  • 22. PAH Phenylketonuria (PKU) Autosomal recessive inheritance - two mutations in trans Metabolic disorder - biochemical profile adds to clinical suspicion
  • 23.
  • 24. exons PAH gene (~79 kb) 13 9 6 3 1 PKU case 1 PKU case 2
  • 25. 868 bp 1,286 bp Exon 6 Exon 7 Two unrelated individuals with the same deletion PKU case 1 PKU case 2 PAH gene
  • 26. Allele 1 1134 bp Allele 2 ~350 bp 100 200 300 case 1 case 2 Allele specific PCR
  • 27. Green: Repeat masker Red: polymorphisms (SNP) CAPITAL: exon Underlined: primers Breakpoint within a SINE: MIRb family Breakpoint within a exon 6 Red box: “CT” is the microhomology at breakpoints.
  • 28. 868 bp 1,286 bp 800 bp 800 bp Partial exon 6 deletion Exon 6 Exon 7 Intron 6 PKU case 1 PKU case 2 Note: breakpoint within an element
  • 29. STK11 Peutz-Jeghers syndrome (PJS) Autosomal dominant inheritance - one mutation Clinical Presentation & Family History
  • 30.
  • 31. exons STK11 gene (~22 kb) +1 -1 0 1 2 3 4,5 6 7 8 9 10
  • 32. +1 -1 0 Possible deletion encompassing exon 3 Designing allele specific PCR 1076 bp exons 2 3 4 AluY Exon3 Intron2 Intron3 Exon2 Exon 4 Intron1 INT1_1F ex2_1F INT2_1F INT2_2F INT2_3F INT3_1R INT3_2R INT3_3R INT3_4R and INT3_5R
  • 33. Exon3 Intron2 Intron3 Exon2 Exon 4 Intron1 INT2_2F INT3_1R INT3_2R INT3_3R INT3_4R and INT3_5R Data indicates a possible deletion of ~1kb. Expected band size in bp Possible exon 3 deletion 678 1130 1324 1580 1595
  • 34. Proximal breakpoint 1170072 in intron 2 Distal breakpoint 1171039 in intron 3 Reference Reference Patient Patient
  • 35. +1 -1 0 Note: breakpoints outside of element A few probes that did not perform ideally were unique exons 2 3 4 1076 bp 967 bp AluY
  • 36. HPRT1 Lesch-Nyhan Syndrome X-linked inheritance - one mutation Clinical Presentation & Family History
  • 37. Lesch-Nyhan case Pending prenatal 24 year old female for carrier testing for a familial HPRT1 mutation ? ?
  • 38. exons HPRT1 gene (~40.5 kb) 1 2 3 4 5 6 7,8 9 +1 -1 0 -5 ? ?
  • 39. 2,780 bp Exon 5 is 18 bp +1 -1 0 -5
  • 40. Exon 5 Max (2757bp) Min (381bp) Int4_1 Int4_2 Int4_3 Int4_4 Intron 4 Intron 5 Int5_4 HPRT_Int5_5R Int5_6 Int5_2 Int5_1 Int5_3 Int5_5 HPRT_Int4_1F HPRT_Int4_2F HPRT_Int5_5R 2745 bp fragment expected in wild type 2657 bp fragment expected in wild type 88bp size difference 500- 400- 300- 500- 400- 300-
  • 41. Mapped a total of 380 bp in the amplicon 157 bp of intron 4 69 bp insertion 154 bp of intron 5 157 bp of intron 4 69 bp insertion
  • 42. The Inserted 69 bpsequence match best on a gene desert on Chromsome 5. ATTCTAGTGATGTTTTCAGGCCTCAGGGGGCGGGTTGGGGGTGGTGGAGGTGGTGTGTATAATATCACT
  • 43.
  • 44. Wt Ex1 Ex2 Ex3 Ex1 Ex2 Ex3 Ex1 Ex2 Ex3 Pt. water Exon 1 and 2 did not amplify for the patient
  • 45. exons EMD gene (~2 kb) +1 -1 0 1 2 3 4 5 6 -2 -3 -4 -5
  • 46. exons 1 2 252 bp +1 -1 0 -5
  • 47. Wt expected band with 1F/2R Would be 480 bp For Wt expected band with 1F/3R Would be 677 bp Band ~370 bp Suggesting ~300 bp deletion Band ~170 bp Suggesting ~300 bp deletion Forward Primer 1F 1F Reverse Primer 2R 3R Wt Pt. H2O Wt Pt. H2O 1kb+ -100 -200 -300 -400 -500 -650 -850 -------1000
  • 48. exon1 exon2 Red nucleotides are deleted. Exons are capitalized Microhomology is limited to two nucleotides, “GC”
  • 49. Deletion encompassing Partial exon 1 and entire exon 2 exons 1 2 252 bp 366 bp +1 -1 0 -5
  • 50.
  • 51. Acknowledgements Directors: Bradford Coffee Ph.D. FACMG Lora Bean Ph.D. FACMG Katie Rudd Ph.D. FACMG Alice Tanner Ph.D. C.G.C. SyedHussainAskree, MBBS, PhD EphremLip Hon Chin, BS (Tech), CLSp (MB)
  • 52.
  • 53.
  • 54.

Editor's Notes

  1. Madhuri Hegde, PhD, FACMG Associate Professor – Scientific Director Emory Genetics Lab Emory University School of Medicine
  2. Madhuri Hegde, PhD, FACMG Associate Professor – Scientific Director Emory Genetics Lab Emory University School of Medicine
  3. Extract from paper: Figure 1 - Lexicon of genomic variation. Descriptors of variation began in the realm of cytogenetics, followed by those from the field of molecular genetics and, most recently, by technologies such as those described in this perspective, which bridge the gap for detection of genomic variants (sometimes called cytogenomics 55 ). The designation of the category &apos;1 kb to submicroscopic&apos; is somewhat arbitrary at both ends, but is used for operational definition. In a broad sense, structural variation has been used to refer to genomic segments both smaller and larger than the narrower operational definition, as illustrated by the large bracket. The focus of recent discoveries has been the subgroup in the midrange (indicated with strong highlighting), but the gradation of shading illustrates that the biological boundaries may really encompass some forms of variation previously recognized from either cytogenetic or molecular genetic approaches. At the molecular level, SNPs can be identified that are representative of the underlying haplotype structure (tagSNPs). As structural variation becomes better integrated with the existing SNP-based linkage disequilibrium maps, it is likely that presence or absence of many structural variants will simply be inferred by typing selected SNPs
  4. The modified Emory designs consist of panels of disease specific groups. For example, genes associated with neuromuscular dystrophy, x-linked intellectual disability and Duchene muscular dystrophy. There are also other panels of genes, for example, associated with cancer, diabetes and hearing loss. Contact us directly for more information on the disorders and genes included.
  5. Contact us directly for more information on the disorders and genes included.